sutent
pfizer new zealand limited - sunitinib malate 50.1mg equivalent to 37.5mg sunitinib; - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to 37.5mg sunitinib excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.
sunitinib pfizer
pfizer new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5mg; - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5mg excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma
sunitinib dr.reddy's
dr reddy's new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5 mg - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5 mg excipient: croscarmellose sodium gelatin iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide water - treatment of advanced renal cell carcinoma treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)
sutent
pfizer new zealand limited - sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib; - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib excipient: croscarmellose sodium gelatin iron oxide red magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.
sutent capsule 37.5mg
pfizer private limited - sunitinib malate 50.100mg eqv sunitinib - capsule - 37.5mg - sunitinib malate 50.100mg eqv sunitinib 37.5mg
sutent sunitinib (as malate) 37.5 mg capsul blister pack.
pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: propylene glycol; iron oxide black; isopropyl alcohol; butan-1-ol; ammonia; ethanol absolute; titanium dioxide; povidone; purified water; potassium hydroxide; mannitol; shellac; croscarmellose sodium; iron oxide yellow; magnesium stearate; sodium lauryl sulfate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg
sutent sunitinib (as malate) 37.5 mg capsule bottle
pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: sodium lauryl sulfate; ethanol absolute; ammonia; butan-1-ol; iron oxide yellow; croscarmellose sodium; potassium hydroxide; mannitol; povidone; shellac; purified water; iron oxide black; titanium dioxide; propylene glycol; isopropyl alcohol; magnesium stearate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).
teva-sunitinib capsule
teva canada limited - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg
sunitinib pfizer
pfizer new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25mg; - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25mg excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma